Replies to post #4452 on GTC Biotherapeutics (fka GTCB)

[mblimon]

"In other words, the CD20 product will entail a different and more expensive kind of selling proposition than going head-to-head against either plasma-derived drugs or recombinant drugs such as NovoSeven that will no longer be actively detailed by the time GTC is in the market."

We may assume that DNA/BIIB's product will be in the market at least 4 years before LFB/GTCB's product comes to market, so the time for DNA?BIIB's product to become generic is not that long. On top of that, a substantially lower price is the best and cheapest promotion you can have, I would say.

[kayamalo1]

While it is generally true the being first matters a lot.
there are many exceptions. When the new drug is substantially better, it sells itself (with adequate marketing) For instance look how lucentis took share from macugen overnight. (or Zyprexa and Ablify in the psychopharm space) Better clinical results are more important to md's than sales rep's spin

[gym gravity]

marketing muscle...it could be they never indend to have to market it themselves.